PDF(Pubmed)
Abstract：
OBJECTIVE: To evaluate the effectiveness of standardised antiretroviral therapy (ART) among different HIV subtypes in people living with HIV/AIDS (PLWHA), and to screen the best ART regimen for this patient population.
METHODS: A retrospective cohort study was performed, and PLWHA residing in Huzhou, China, between 2018 and 2020, were enrolled.
METHODS: Data from 625 patients, who were newly diagnosed with HIV/AIDS in the AIDS Prevention and Control Information System in Huzhou between 2018 and 2020, were reviewed.
UNASSIGNED: Data regarding demographic characteristics and laboratory investigation results were collected. Immune system recovery was used to assess the effectiveness of ART, and an increased percentage of CD4+ T lymphocyte counts >30% after receiving ART for >1 year was determined as immunopositive. A multiple logistic regression model was used to comprehensively quantify the association between PLWHA immunological response status and virus subtype. In addition, the joint association between different subtypes and treatment regimens on immunological response status was investigated.
RESULTS: Among 326 enrolled PLWHA with circulating recombinant forms (CRFs) CRF01_AE, CRF07_BC and other HIV/AIDS subtypes, the percentages of immunopositivity were 74.0%, 65.6% and 69.6%, respectively. According to multivariate logistic regression models, there was no difference in the immunological response between patients with CRF01_AE, CRF07_BC and other subtypes of HIV/AIDS who underwent ART (CRF07_BC: adjusted OR (aOR) (95% CI) = 0.8 (0.4 to 1.4); other subtypes: aOR (95% CI) = 1.2 (0.6 to 2.3)). There was no evidence of an obvious joint association between HIV subtypes and ART regimens on immunological response.
CONCLUSIONS: Standardised ART was beneficial to all PLWHA, regardless of HIV subtypes, although it was more effective, to some extent, in PLWHA with CRF01_AE.
METHODS: A retrospective cohort study was performed, and PLWHA residing in Huzhou, China, between 2018 and 2020, were enrolled.
METHODS: Data from 625 patients, who were newly diagnosed with HIV/AIDS in the AIDS Prevention and Control Information System in Huzhou between 2018 and 2020, were reviewed.
UNASSIGNED: Data regarding demographic characteristics and laboratory investigation results were collected. Immune system recovery was used to assess the effectiveness of ART, and an increased percentage of CD4+ T lymphocyte counts >30% after receiving ART for >1 year was determined as immunopositive. A multiple logistic regression model was used to comprehensively quantify the association between PLWHA immunological response status and virus subtype. In addition, the joint association between different subtypes and treatment regimens on immunological response status was investigated.
RESULTS: Among 326 enrolled PLWHA with circulating recombinant forms (CRFs) CRF01_AE, CRF07_BC and other HIV/AIDS subtypes, the percentages of immunopositivity were 74.0%, 65.6% and 69.6%, respectively. According to multivariate logistic regression models, there was no difference in the immunological response between patients with CRF01_AE, CRF07_BC and other subtypes of HIV/AIDS who underwent ART (CRF07_BC: adjusted OR (aOR) (95% CI) = 0.8 (0.4 to 1.4); other subtypes: aOR (95% CI) = 1.2 (0.6 to 2.3)). There was no evidence of an obvious joint association between HIV subtypes and ART regimens on immunological response.
CONCLUSIONS: Standardised ART was beneficial to all PLWHA, regardless of HIV subtypes, although it was more effective, to some extent, in PLWHA with CRF01_AE.
摘要：
目的：评估标准化抗逆转录病毒疗法（ART）在HIV/AIDS感染者（PLWHA）的不同HIV亚型中的有效性，并为该患者人群筛选最佳ART方案。
方法：进行了一项回顾性队列研究，和居住在湖州的PLWHA，中国,在2018年至2020年期间，均已注册。
方法：来自625名患者的数据，对湖州市艾滋病防治信息系统2018-2020年间新确诊的HIV/AIDS患者进行了综述。
■收集有关人口统计学特征和实验室调查结果的数据。免疫系统恢复被用来评估ART的有效性，接受ART治疗1年后，CD4+T淋巴细胞计数增加的百分比>30%被确定为免疫阳性。使用多元逻辑回归模型来全面量化PLWHA免疫应答状态与病毒亚型之间的关联。此外,研究了不同亚型和治疗方案对免疫应答状态的联合关联.
结果：在326名具有循环重组形式（CRF）CRF01_AE的注册PLWHA中，CRF07_BC和其他HIV/AIDS亚型，免疫阳性率为74.0%,65.6%和69.6%，分别。根据多元逻辑回归模型，CRF01_AE患者之间的免疫反应没有差异，CRF07_BC和其他接受ART的HIV/AIDS亚型（CRF07_BC：校正OR（aOR）（95％CI）=0.8（0.4至1.4）；其他亚型：aOR（95％CI）=1.2（0.6至2.3））。没有证据表明HIV亚型和ART方案对免疫反应有明显的联合关联。
结论：标准化ART对所有PLWHA有益，不管HIV亚型，虽然更有效,在某种程度上,在PLWHA中使用CRF01_AE。
方法：进行了一项回顾性队列研究，和居住在湖州的PLWHA，中国,在2018年至2020年期间，均已注册。
方法：来自625名患者的数据，对湖州市艾滋病防治信息系统2018-2020年间新确诊的HIV/AIDS患者进行了综述。
■收集有关人口统计学特征和实验室调查结果的数据。免疫系统恢复被用来评估ART的有效性，接受ART治疗1年后，CD4+T淋巴细胞计数增加的百分比>30%被确定为免疫阳性。使用多元逻辑回归模型来全面量化PLWHA免疫应答状态与病毒亚型之间的关联。此外,研究了不同亚型和治疗方案对免疫应答状态的联合关联.
结果：在326名具有循环重组形式（CRF）CRF01_AE的注册PLWHA中，CRF07_BC和其他HIV/AIDS亚型，免疫阳性率为74.0%,65.6%和69.6%，分别。根据多元逻辑回归模型，CRF01_AE患者之间的免疫反应没有差异，CRF07_BC和其他接受ART的HIV/AIDS亚型（CRF07_BC：校正OR（aOR）（95％CI）=0.8（0.4至1.4）；其他亚型：aOR（95％CI）=1.2（0.6至2.3））。没有证据表明HIV亚型和ART方案对免疫反应有明显的联合关联。
结论：标准化ART对所有PLWHA有益，不管HIV亚型，虽然更有效,在某种程度上,在PLWHA中使用CRF01_AE。
